LRRK2 and Parkinson disease: Following evidence of gain-of-function increase in LRRK2 kinase activity in mutation carriers, promising pre-clinical studies have already demonstrated neuroprotective properties of LRRK2 kinase inhibitors, including reduced alpha-synuclein aggregation, reduced dopaminergic neurodegeneration, and reduced microglial and macrophage activation.[6] Considering the enormous potential future application to LRRK2 p.G2019S –related PD, determining the relevance in diverse populations is imperative.